<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>CrashDash ‚Ä¢ TRLS.L APEX Profile</title>
    <style>
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body { 
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, sans-serif;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            padding: 20px;
            color: #333;
        }
        .container { max-width: 1200px; margin: 0 auto; }
        
        .header-card {
            background: white;
            border-radius: 16px;
            padding: 30px;
            margin-bottom: 20px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }
        .ticker-badge {
            display: inline-block;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 8px 16px;
            border-radius: 20px;
            font-weight: bold;
            font-size: 18px;
            margin-bottom: 10px;
        }
        .company-name { font-size: 32px; font-weight: 700; margin-bottom: 8px; }
        .company-meta {
            display: flex;
            gap: 20px;
            margin-top: 15px;
            flex-wrap: wrap;
        }
        .meta-item {
            display: flex;
            align-items: center;
            gap: 8px;
            padding: 8px 16px;
            background: #f7fafc;
            border-radius: 8px;
            font-size: 14px;
        }
        .meta-icon { font-size: 18px; }
        
        .score-hero {
            background: linear-gradient(135deg, #f093fb 0%, #f5576c 100%);
            color: white;
            border-radius: 16px;
            padding: 40px;
            margin-bottom: 20px;
            text-align: center;
            box-shadow: 0 10px 40px rgba(0,0,0,0.15);
        }
        .action-display {
            margin-bottom: 20px;
        }
        .scores-row {
            display: flex;
            justify-content: center;
            gap: 40px;
            margin: 30px 0;
        }
        .score-circle {
            width: 140px;
            height: 140px;
            border-radius: 50%;
            background: white;
            display: flex;
            flex-direction: column;
            align-items: center;
            justify-content: center;
            box-shadow: 0 4px 15px rgba(0,0,0,0.1);
        }
        .score-number {
            font-size: 48px;
            font-weight: 800;
            line-height: 1;
        }
        .score-label { font-size: 12px; color: #666; margin-top: 5px; }
        .timing-badge-large {
            display: inline-block;
            padding: 15px 40px;
            border-radius: 30px;
            font-weight: 700;
            font-size: 24px;
            background: rgba(255,255,255,0.2);
            backdrop-filter: blur(10px);
            color: white;
            margin: 20px 0;
        }
        .thesis-line {
            font-size: 18px;
            font-weight: 600;
            color: white;
            background: rgba(255,255,255,0.15);
            backdrop-filter: blur(10px);
            padding: 20px;
            border-radius: 12px;
            margin-top: 20px;
        }
        
        .factors-list {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 15px;
            margin-top: 20px;
        }
        .factor-item {
            background: white;
            padding: 15px;
            border-radius: 12px;
            display: flex;
            align-items: center;
            gap: 10px;
            font-size: 14px;
        }
        .factor-icon { font-size: 20px; }
        
        .cards-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 20px;
            margin-bottom: 20px;
        }
        .card {
            background: white;
            border-radius: 16px;
            padding: 25px;
            box-shadow: 0 4px 20px rgba(0,0,0,0.08);
        }
        .card-title {
            font-size: 18px;
            font-weight: 600;
            margin-bottom: 20px;
            display: flex;
            align-items: center;
            gap: 10px;
        }
        .card-icon { font-size: 24px; }
        
        .stat-row {
            display: flex;
            justify-content: space-between;
            padding: 12px 0;
            border-bottom: 1px solid #f0f0f0;
        }
        .stat-row:last-child { border-bottom: none; }
        .stat-label { color: #666; font-size: 14px; }
        .stat-value { font-weight: 600; font-size: 16px; }
        
        .rally-badge {
            display: inline-block;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 12px;
            font-weight: 600;
            text-transform: uppercase;
        }
        
        .risk-indicator {
            display: flex;
            align-items: center;
            gap: 15px;
            padding: 15px;
            border-radius: 12px;
            margin-bottom: 10px;
        }
        .risk-high { background: #fee2e2; }
        .risk-icon { font-size: 24px; }
        
        .reason-item {
            padding: 15px;
            background: #f9fafb;
            border-radius: 8px;
            margin-bottom: 12px;
        }
        
        .tag {
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 11px;
            font-weight: 600;
        }
        
        .footer {
            background: white;
            border-radius: 16px;
            padding: 20px;
            text-align: center;
            color: #666;
            font-size: 13px;
            box-shadow: 0 4px 20px rgba(0,0,0,0.08);
            margin-top: 20px;
        }
        
        .alert-box {
            background: #fef3c7;
            border-left: 4px solid #f59e0b;
            padding: 15px;
            border-radius: 8px;
            margin: 15px 0;
        }
    </style>
</head>
<body>
    <div class="container">
        
        <!-- Header Card -->
        <div class="header-card">
            <div class="ticker-badge">TRLS.L</div>
            <div class="company-name">Trellus Health plc</div>
            <div class="company-meta">
                <div class="meta-item">
                    <span class="meta-icon">‚ñ†</span>
                    <span><strong>Sector:</strong> Healthcare</span>
                </div>
                <div class="meta-item">
                    <span class="meta-icon">¬£</span>
                    <span><strong>Market Cap:</strong> ¬£646,033</span>
                </div>
                <div class="meta-item">
                    <span class="meta-icon">‚ó∑</span>
                    <span><strong>Days Active:</strong> 14 days</span>
                </div>
            </div>
        </div>

        <!-- Action & Score Hero Section -->
        <div class="score-hero">
            <div class="action-display">
                <span style="font-size: 32px; font-weight: 800; color: white;">‚óâ WATCH</span>
            </div>
            
            <div class="scores-row">
                <div class="score-circle">
                    <div class="score-number" style="color: #ef4444;">42</div>
                    <div class="score-label">APEX SCORE</div>
                </div>
                <div class="score-circle">
                    <div class="score-number" style="color: #f59e0b;">50</div>
                    <div class="score-label">CONFIDENCE</div>
                </div>
            </div>
            
            <div class="timing-badge-large">
                Timing: <span class="rally-badge" style="background: #fef3c7; color: #92400e;">EARLY BUILD</span>
            </div>
            
            <div class="thesis-line">
                WATCH - EARLY_BUILD timing with 42/100 opportunity score
            </div>
        </div>

        <!-- ==================== CRASHDASH INTELLIGENCE - PANIC HUNTER VIEW ==================== -->
        
        <div class="card" style="background: linear-gradient(135deg, #fee2e2 0%, #fecaca 100%); border: 2px solid #ef4444;">
            <div class="card-title" style="color: #0f172a;">
                <span class="card-icon">üè≠</span>
                CrashDash Intelligence ‚Ä¢ Industrials
            </div>
            
            <!-- Fear Meter -->
            <div style="background: white; padding: 24px; border-radius: 14px; margin-bottom: 20px; text-align: center;">
                <div style="font-size: 16px; font-weight: 700; color: #1e293b; margin-bottom: 16px;">üî• PANIC METER</div>
                <div style="display: flex; justify-content: center; align-items: center; gap: 20px; margin-bottom: 16px;">
                    <div style="width: 160px; height: 160px; border-radius: 50%; background: conic-gradient(#ef4444 288.0deg, #e5e7eb 288.0deg); display: flex; align-items: center; justify-content: center; box-shadow: 0 4px 20px rgba(0,0,0,0.15);">
                        <div style="width: 130px; height: 130px; border-radius: 50%; background: white; display: flex; flex-direction: column; align-items: center; justify-content: center;">
                            <div style="font-size: 48px; font-weight: 800; color: #ef4444;">80</div>
                            <div style="font-size: 12px; color: #64748b; font-weight: 600;">PANIC SCORE</div>
                        </div>
                    </div>
                    <div style="text-align: left; max-width: 400px;">
                        <div style="font-size: 18px; font-weight: 700; color: #ef4444; margin-bottom: 12px;">EXTREME PANIC</div>
                        <div style="font-size: 14px; color: #475569; line-height: 1.6; margin-bottom: 12px;">üî¥ Capitulation zone - contrarian opportunity if fundamentals intact</div>
                        <div style="font-size: 13px; color: #64748b;">
                            <div>üíî Price: 40/40</div>
                            <div>üìâ Volume: 14/20</div>
                            <div>üîá Social: 6/20</div>
                            <div>üì∞ News: 20/20</div>
                        </div>
                    </div>
                </div>
                
                <!-- CrashHunter Signals -->
                <div style="margin-top: 20px;">
                    <span style="display: inline-block; background: #ef4444; color: white; padding: 6px 14px; border-radius: 20px; font-size: 13px; font-weight: 700; margin: 4px;">üî¥ Panic 80/100</span><span style="display: inline-block; background: #10b981; color: white; padding: 6px 14px; border-radius: 20px; font-size: 13px; font-weight: 700; margin: 4px;">üìä Building</span>
                </div>
                
                <!-- Opportunity Flag -->
                <div style="margin-top: 20px; padding: 16px; background: linear-gradient(135deg, #10b981 0%, #059669 100%); border-radius: 10px; color: white; font-weight: 700; font-size: 16px;">üéØ üî• EXTREME PANIC + Intact timing = Prime contrarian entry zone</div>
            </div>
            
            <!-- Contrarian Compression Energy Panel -->
            
            <!-- Contrarian Compression Energy Panel -->
            <div style="background: linear-gradient(135deg, #d1fae5 0%, #a7f3d0 100%); padding: 24px; border-radius: 14px; margin-bottom: 20px; border: 3px solid #10b981;">
                <div style="display: flex; align-items: center; gap: 12px; margin-bottom: 20px;">
                    <span style="font-size: 32px;">‚ö°</span>
                    <div style="flex: 1;">
                        <div style="font-size: 20px; font-weight: 800; color: #0f172a; margin-bottom: 4px;">
                            CONTRARIAN COMPRESSION SCORE
                        </div>
                        <div style="font-size: 13px; color: #475569; font-weight: 600;">
                            Signal Congestion Framework ‚Ä¢ Compression = Explosive Potential
                        </div>
                    </div>
                </div>
                
                <!-- Main Score Display -->
                <div style="background: white; padding: 24px; border-radius: 12px; margin-bottom: 20px; text-align: center;">
                    <div style="display: flex; justify-content: center; align-items: center; gap: 30px;">
                        <!-- Circular gauge -->
                        <div style="width: 140px; height: 140px; border-radius: 50%; background: conic-gradient(#10b981 136.8deg, #e5e7eb 136.8deg); display: flex; align-items: center; justify-content: center; box-shadow: 0 4px 20px rgba(0,0,0,0.15);">
                            <div style="width: 110px; height: 110px; border-radius: 50%; background: white; display: flex; flex-direction: column; align-items: center; justify-content: center;">
                                <div style="font-size: 42px; font-weight: 800; color: #10b981;">38</div>
                                <div style="font-size: 11px; color: #64748b; font-weight: 600;">/ 100</div>
                            </div>
                        </div>
                        
                        <!-- Key metrics -->
                        <div style="text-align: left;">
                            <div style="font-size: 16px; font-weight: 700; color: #10b981; margin-bottom: 12px;">üü¢ MILD COMPRESSION (Top 50% - WATCHLIST)</div>
                            <div style="font-size: 13px; color: #475569; line-height: 1.8;">
                                <div><strong>0.2</strong> signals/week</div>
                                <div><strong>3</strong> RSI &lt; 20 events</div>
                                <div><strong>1</strong> escalations detected</div>
                                <div style="color: #10b981; font-weight: 700; margin-top: 6px;">
                                    üíé Historical pop: <strong>+692%</strong>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
                
                <!-- Component Breakdown -->
                <div style="background: white; padding: 20px; border-radius: 12px; margin-bottom: 20px;">
                    <div style="font-weight: 700; color: #1e293b; margin-bottom: 16px; font-size: 15px;">
                        üìä 5-COMPONENT BREAKDOWN
                    </div>
                    
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">compression</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">14/40</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 35.0%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">0.2 signals/week | 3 RSI<20 | 1 escalations | üéØ MILD COMPRESSION</div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">intensification</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">5/20</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 25.0%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;"></div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">volume death</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">5/15</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 33.33333333333333%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">Elevated volume - Some activity</div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">pop potential</div>
                        <div style="font-weight: 800; font-size: 15px; color: #ef4444;">14/15</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #ef4444; height: 100%; width: 93.33333333333333%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">BIG POPPER - Historical 5x+ (692%)</div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">accumulation</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">0/10</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 0.0%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">No accumulation</div>
                </div>
                
                </div>
                
                <!-- Contrarian Philosophy -->
                <div style="background: rgba(255,255,255,0.7); padding: 16px; border-radius: 10px; border-left: 4px solid #10b981;">
                    <div style="font-weight: 700; color: #0f172a; margin-bottom: 8px; font-size: 14px;">
                        üéØ CONTRARIAN WISDOM
                    </div>
                    <div style="font-size: 13px; color: #334155; line-height: 1.6;">
                        <strong>Signal congestion = Compression energy = Explosive potential.</strong><br>
                        When multiple crash signals cluster together with extreme RSI and proven rally history, 
                        it creates a compressed spring effect. More panic = More opportunity for contrarians.
                        <div style="margin-top: 8px; padding: 10px; background: rgba(239,68,68,0.1); border-radius: 6px; font-size: 12px;">
                            <strong style="color: #10b981;">Theory:</strong> High compression scores (60+) historically precede 
                            explosive 10-20x moves when catalysts arrive. This is the foundation of crash hunting.
                        </div>
                    </div>
                </div>
            </div>
            
            
            <!-- Fear vs Facts Contrarian View -->
            <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 15px; margin-bottom: 20px;">
                <div style="background: #fee2e2; padding: 18px; border-radius: 12px; border-left: 4px solid #ef4444;">
                    <div style="font-weight: 700; color: #991b1b; margin-bottom: 12px; font-size: 15px;">üò± FEAR (What Panic Shows)</div>
                    <div style="color: #7f1d1d;">
                        <div style="padding: 8px 0; font-size: 14px; line-height: 1.5;">‚Ä¢ üíî Price destruction: 40/40 points</div><div style="padding: 8px 0; font-size: 14px; line-height: 1.5;">‚Ä¢ üì∞ Negative news: 20/20 points</div>
                    </div>
                </div>
                <div style="background: #dcfce7; padding: 18px; border-radius: 12px; border-left: 4px solid #10b981;">
                    <div style="font-weight: 700; color: #065f46; margin-bottom: 12px; font-size: 15px;">üìä FACTS (What Data Shows)</div>
                    <div style="color: #064e3b;">
                        <div style="color: #64748b; font-size: 14px;">Limited historical data</div>
                    </div>
                </div>
            </div>
            
            <!-- Contrarian Verdict -->
            <div style="background: white; padding: 18px; border-radius: 12px; margin-bottom: 20px; border-left: 4px solid #6366f1;">
                <div style="font-weight: 700; color: #4338ca; margin-bottom: 10px; font-size: 15px;">‚öñÔ∏è Contrarian Verdict</div>
                <div style="font-size: 15px; color: #1e293b; line-height: 1.6; font-weight: 600;">
                    üéØ CONTRARIAN OPPORTUNITY - Fear dominates but facts support recovery potential
                </div>
            </div>
            
            <!-- Industry Crash Patterns -->
            <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 15px; margin-bottom: 20px;">
                <div style="background: white; padding: 18px; border-radius: 12px;">
                    <div style="font-weight: 700; color: #1e293b; margin-bottom: 12px; font-size: 15px;">‚ö†Ô∏è Crash Patterns (Industrials)</div>
                    <div style="font-size: 13px; color: #475569; line-height: 1.8;">
                        <div>‚Ä¢ Order book decline or cancellations</div><div>‚Ä¢ Margin compression (input costs)</div><div>‚Ä¢ Cyclical demand weakness</div>
                    </div>
                    
                </div>
                <div style="background: white; padding: 18px; border-radius: 12px;">
                    <div style="font-weight: 700; color: #1e293b; margin-bottom: 12px; font-size: 15px;">üöÄ Recovery Paths</div>
                    <div style="font-size: 13px; color: #475569; line-height: 1.8;">
                        <div>‚Ä¢ Order book growth or new contracts</div><div>‚Ä¢ Margin recovery (efficiency gains)</div><div>‚Ä¢ Cyclical upturn (capex recovery)</div>
                    </div>
                </div>
            </div>
            
            <!-- Catalyst Pipeline -->
            <div style="background: rgba(255,255,255,0.5); padding: 18px; border-radius: 12px; margin-bottom: 20px;">
                <div style="font-weight: 700; color: #1e293b; margin-bottom: 14px; font-size: 15px;">üìÖ Catalyst Pipeline</div>
                
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Proposed issue of Secured Convertible Loan Notes</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Proposed issue of Secured Convertible Loan Notes</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Finance update</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Contract signed with second leading CRO</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Contract Signed with Leading Global CRO</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            </div>
            
            <!-- CrashDash Decision Matrix -->
            <div style="background: white; padding: 20px; border-radius: 12px; border: 3px solid #ef4444;">
                <div style="font-weight: 700; color: #1e293b; margin-bottom: 16px; font-size: 16px; text-align: center;">
                    üéØ CRASHDASH DECISION: <span style="color: #ef4444; font-size: 20px;">WATCH</span>
                </div>
                <div style="font-size: 15px; color: #475569; text-align: center; margin-bottom: 20px; font-weight: 600;">
                    ‚è≥ Monitor for timing regime change or panic escalation
                </div>
                <div style="background: #f8fafc; padding: 16px; border-radius: 10px;">
                    <div style="font-weight: 700; color: #64748b; margin-bottom: 12px; font-size: 13px;">CHECKLIST (4/5 pass)</div>
                    
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">üî¥</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Panic Score</div>
                    <div style="font-size: 13px; color: #10b981; font-weight: 600;">80/100</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">‚úÖ</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Timing Regime</div>
                    <div style="font-size: 13px; color: #10b981; font-weight: 600;">EARLY_BUILD</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">‚ö†Ô∏è</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">APEX Quality</div>
                    <div style="font-size: 13px; color: #ef4444; font-weight: 600;">42/100</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">üéØ</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Data Confidence</div>
                    <div style="font-size: 13px; color: #10b981; font-weight: 600;">50/100</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">üè≠</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Industry Pattern</div>
                    <div style="font-size: 13px; color: #10b981; font-weight: 600;">0 active</div>
                </div>
            </div>
            
                </div>
            </div>
        </div>
        

        <!-- ==================== AI TRADER INTELLIGENCE (TOP) - TRADER BRIEF V2 ==================== -->
        

        <!-- Decision Summary -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚óÜ</span>
                Why This Matters
            </div>
            <div class="stat-row"><span>‚Ä¢ APEX 42/100 indicates moderate opportunity quality</span></div><div class="stat-row"><span>‚Ä¢ Timing regime: EARLY_BUILD</span></div><div class="stat-row"><span>‚Ä¢ Historical profile: 0 rallies, 0% best run</span></div>
            
            <div class="alert-box" style="margin-top: 20px;">
                <strong>‚ñ≥ Main Risk:</strong> Confidence 50/100 - full data loaded
            </div>
            
            <div style="margin-top: 20px;">
                <strong>‚óâ Watch Next:</strong>
                <div style="padding: 8px 0;">‚Ä¢ RNS catalysts (funding/operational updates)</div><div style="padding: 8px 0;">‚Ä¢ Volume expansion confirmation</div><div style="padding: 8px 0;">‚Ä¢ Timing regime change signals</div>
            </div>
        </div>

        <!-- ==================== TECHNICAL DETAILS (COLLAPSIBLE) ==================== -->
        
        <div class="card">
          <details style="cursor:pointer;">
            <summary style="font-weight:800; font-size:16px; list-style:none; padding: 10px; background: #f9fafb; border-radius: 8px;">
              üîß Technical Analysis & Scoring Details
            </summary>
            <div style="margin-top:14px;">
              
            <!-- Scoring Breakdown -->
            <div class="card-title" style="margin-top: 20px;">
                <span class="card-icon">‚ñ£</span>
                APEX Score Breakdown
            </div>
            <div class="factors-list">
                <div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Moderate Technical Setup</strong><br><small>Chart quality: 9/20 ‚Ä¢ Score: 11/25 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Massive recovery potential</strong><br><small>Down 92.6% from peak ‚Ä¢ Score: 19/20 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Strong volume</strong><br><small>2.3x average ‚Ä¢ Score: 10/10 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>No history</strong><br><small>0 previous rallies ‚Ä¢ Score: 0/15 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Modest upside</strong><br><small>Historical best: +0% ‚Ä¢ Score: 2/20 points</small></span></div>

            </div>
            
            <div style="margin-top: 40px;"></div>
            
            <!-- Exhaustion Metrics -->
            <div class="card-title">
                <span class="card-icon">üìà</span>
                Rally Cycle Position
            </div>
            <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(150px, 1fr)); gap: 15px; margin: 20px 0;">
                <div style="padding: 15px; background: linear-gradient(135deg, #10b981 0%, #059669 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Current Position</div>
                    <div style="font-size: 32px; font-weight: 800;">0%</div>
                    <div style="font-size: 11px; opacity: 0.8;">from entry</div>
                </div>
                <div style="padding: 15px; background: linear-gradient(135deg, #3b82f6 0%, #1d4ed8 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Typical Rally</div>
                    <div style="font-size: 32px; font-weight: 800;">0%</div>
                    <div style="font-size: 11px; opacity: 0.8;">historical avg</div>
                </div>
                <div style="padding: 15px; background: linear-gradient(135deg, #f59e0b 0%, #d97706 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Exhaustion Level</div>
                    <div style="font-size: 32px; font-weight: 800;">0.0x</div>
                    <div style="font-size: 11px; opacity: 0.8;">vs average</div>
                </div>
            </div>
        
            </div>
          </details>
        </div>
        

        <!-- Reasons Buy/Sell -->
        <div class="cards-grid">
            <div class="card">
                <div class="card-title">
                    <span class="card-icon" style="color: #10b981;">‚ñ≤</span>
                    Reasons to Buy
                </div>
                
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Early stage positioning offers best R:R if catalysts appear</span>
                    <span class="tag" style="background: #f59e0b; color: white;">‚ö° Medium Strength</span>
                </div>
                <div style="font-size: 12px; color: #666;">timing=EARLY BUILD ‚Ä¢ current return=0.0%</div>
            </div>
            
            </div>
            
            <div class="card">
                <div class="card-title">
                    <span class="card-icon" style="color: #ef4444;">‚ñº</span>
                    Reasons to Sell / Avoid
                </div>
                <div style="color: #666; font-style: italic;">No major sell signals.</div>
            </div>
        </div>

        <!-- Trade Plans -->
        <div class="cards-grid">
            <div class="card">
                <div class="card-title">
                    <span class="card-icon">üìä</span>
                    Short-Term Trader Playbook
                </div>
                <div style="background: linear-gradient(135deg, #f093fb 0%, #f5576c 20%); color: white; padding: 15px; border-radius: 8px; margin-bottom: 15px;">
                    <div style="font-size: 18px; font-weight: 600; margin-bottom: 5px;">Watch / Starter</div>
                    <div style="font-size: 14px; opacity: 0.9;">Wait for base + catalyst confirmation; starter position only</div>
                </div>
                <div style="padding: 12px; background: #f9fafb; border-radius: 6px; margin-bottom: 10px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Position Size</div>
                    <div style="font-weight: 600;">0-1% until CONFIRMED</div>
                </div>
                <div style="padding: 12px; background: #fef2f2; border-radius: 6px; margin-bottom: 10px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Risk Management</div>
                    <div style="font-weight: 600; color: #dc2626;">Invalidation = breaks recent lows / dilution / suspension</div>
                </div>
                <div style="padding: 12px; background: #f0fdf4; border-radius: 6px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Exit Strategy</div>
                    <div style="font-weight: 600; color: #059669;">Scale out 25% at +15%, 25% at +50%, runner above</div>
                </div>
            </div>
            
            <div class="card">
                <div class="card-title">
                    <span class="card-icon">üíº</span>
                    Long-Term Investor Playbook
                </div>
                <div style="background: linear-gradient(135deg, #667eea 0%, #764ba2 100%); color: white; padding: 15px; border-radius: 8px; margin-bottom: 15px; text-align: center;">
                    <div style="font-size: 32px; margin-bottom: 5px;">‚úó</div>
                    <div style="font-size: 18px; font-weight: 600;">Not Recommended for Investors</div>
                </div>
                <div style="padding: 15px; background: #f9fafb; border-radius: 8px; font-size: 14px; line-height: 1.6;">
                    <strong style="color: #667eea;">üìã Investment Thesis:</strong><br>
                    Unlock after AI triangulation + CONFIRMED timing<br><br>
                    <strong style="color: #667eea;">‚è≥ Time Horizon:</strong><br>
                    N/A<br><br>
                    <strong style="color: #ef4444;">üõ°Ô∏è Exit Rule:</strong><br>
                    N/A
                </div>
            </div>
        </div>

        <!-- Commentary -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚óê</span>
                Executive Commentary
            </div>
            <div style="line-height: 1.6; margin-bottom: 20px;">
                This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows EARLY_BUILD timing with 42/100 APEX score. Historical data shows 0 rallies averaging 0% upside. Current position: +0.0%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.
            </div>
            
            <div style="margin-top: 20px;">
                <strong style="color: #10b981;">‚ñ≤ Bull Case:</strong>
                <div style="padding: 8px 0;">‚Ä¢ Early regime often offers best risk/reward</div>
            </div>
            
            <div style="margin-top: 20px;">
                <strong style="color: #ef4444;">‚ñº Bear Case:</strong>
                <div style="padding: 8px 0;">‚Ä¢ Monitor for breakdown signals</div>
            </div>
            
            <div style="margin-top: 20px; padding: 15px; background: #f0f9ff; border-radius: 8px;">
                <strong>‚ó∑ Timing Translation:</strong><br>
                Early accumulation phase. Watch for confirmation before committing size.
            </div>
            
            <div style="margin-top: 20px; padding: 15px; background: #fef3c7; border-radius: 8px;">
                <strong>‚óé Confidence Explained:</strong><br>
                Confidence 50/100 reflects full data quality with triangulation loaded.
            </div>
        </div>

        <!-- Data Quality Warning -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚ñ≥</span>
                Data Quality Notice
            </div>
            <div class="alert-box">
                <strong>Analysis Mode:</strong> HISTORICAL_ONLY<br>
                <strong>Impact:</strong> HIGH
            </div>
            <div class="risk-indicator risk-high"><span class="risk-icon">‚ñ≥</span><div><div style="font-weight: 600;">AI insights from Groq LLM</div></div></div>

            <div style="margin-top: 15px; font-size: 13px; color: #666;">
                Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk.
            </div>
        </div>

        <!-- ==================== TOP 5 RECENT RNS NEWS ==================== -->
        
        <div class="card" style="border-top: 3px solid #3b82f6;">
            <div class="card-title" style="margin-bottom: 20px;">
                <span class="card-icon">üì∞</span>
                Top 5 Recent RNS Announcements
            </div>
            <div style="margin-top: 15px;">
                
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">1</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #1
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üìä</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Proposed issue of Secured Convertible Loan Notes</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">GROK: 90/100 ‚Ä¢ NEUTRAL</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    CORPORATE NEWS: Proposed issue of Secured Convertible Loan Notes | üìä Neutral informational update
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">30th Dec 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">5:00 pm</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                <div style="
                    margin: 16px 0;
                    padding: 14px;
                    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
                    border-radius: 10px;
                    border-left: 4px solid #3b82f6;
                ">
                    <h4 style="
                        font-size: 13px;
                        color: #1e293b;
                        margin-bottom: 12px;
                        font-weight: 700;
                        display: flex;
                        align-items: center;
                        gap: 8px;
                    ">
                        <span style="font-size: 16px;">ü§ñ</span> GROK INTELLIGENCE ANALYSIS
                        <span style="
                            display: inline-block;
                            background: #3b82f6;
                            color: white;
                            padding: 2px 8px;
                            border-radius: 10px;
                            font-size: 11px;
                            font-weight: 800;
                        ">90/100</span>
                    </h4>
                    
                    <div style="display: grid; gap: 10px;">
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">EVENT TYPE:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">CORPORATE NEWS: Proposed issue of Secured Convertible Loan Notes</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">TRADING VIEW:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üìä Neutral informational update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RISK LEVEL:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üîµ NEUTRAL: Balanced or routine update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RECOMMENDED:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">üìã HOLD: Monitor for developing patterns in announcements</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">COMPANY HEALTH:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">‚ö†Ô∏è CRITICAL: Serious company health concerns - potential distress signal</div>
                        </div>
                    </div>
                </div>
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Trading Days</td>
                    </tr>
                    
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">KEY METRICS:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">90%, 70%, 99%</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
30 Dec 2025 17:00
RNS Number : 1958N
Trellus Health PLC
30 December 2025
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO PURCHASE AND/OR SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN TRELLUS HEALTH PLC OR ANY OTHER ENTITY IN ANY JURISDICTION. NEITHER THIS ANNOUNCEMENT NOR THE FACT OF ITS DISTRIBUTION, SHALL FORM THE BASIS OF, OR BE RELIED ON IN CONNECTION WITH ANY INVESTMENT DECISION IN RESPECT OF TRELLUS HEALTH PLC OR ANY OTHER ENTITY.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION RELATING TO TRELLUS HEALTH PLC AND ITS SECURITIES FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (596/2014/EU) AS IT FORMS PART OF THE DOMESTIC LAW OF THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("EUWA") AND AS MODIFIED BY OR UNDER THE EUWA OR OTHER DOMESTIC LAW, INCLUDING BUT NOT LIMITED TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR), AS PERMITTED BY UK MAR. THIS INSIDE INFORMATION IS SET OUT IN THIS ANNOUNCEMENT. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION RELATING TO TRELLUS HEALTH PLC AND ITS SECURITIES, WHICH IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Trellus Health plc
("
Trellus Health
" or the "
Company
")
Proposed issue of Secured Convertible Loan Notes to raise up to ¬£5 million
and grant of Warrants
Definitions contained within Appendix I to this Announcement apply, unless the context requires otherwise
Trellus Health plc (AIM: TRLS), a healthcare company delivering Trellus Elevate¬Æ, a digital platform that integrates data analytics with personalised, scientifically proven resilience programs and value-based solutions to manage complex chronic conditions, announces that it proposes to issue ¬£5 million Secured Convertible Loan Notes (the Facility) to an institutional investor to extend the Company's cash runway, subject to Shareholder approval. The Company had previously announced that it had entered into an unsecured loan agreement with its long-standing substantial shareholder, Mount Sinai, with a principal amount of US$600,000 which
supported the continued execution of the Company's commercial strategy and extend its near-term cash runway to late January 2026. Since this time, the Company has been in active discussions with the aim of securing additional funds to extend the cash runway further, hence the
Secured Convertible Loan Notes.
The Facility is structured to provide Trellus Health with flexible, staged access to capital to support its operational and commercial objectives, while managing dilution and aligning funding availability with execution milestones.
Key features include:
¬∑
12 month facility of up to ¬£5 million in principal, available in multiple tranches;
¬∑
conversion at a discount to market price at the time of conversion, with tranche-specific terms; and
¬∑
warrant coverage issued in connection with each tranche.
Further details of the Facility are set out below and in the Circular, which is to be posted to Shareholders tomorrow and will be made available on the Company's website at
trellushealth.com/investors
.
The Board believes that the Facility:
¬∑
strengthens the Company's near-term funding position while preserving flexibility over the timing and scale of capital drawdowns;
¬∑
enables the Company to align conversions with market conditions;
¬∑
supports the Company's ongoing commercial initiatives and partnership discussions; and
¬∑
reflects continued access to institutional capital from a financial investor familiar with structured growth financing.
The Directors also consider the inclusion of warrant coverage (details of which are provided below) provides additional alignment between investor returns and the longer-term performance of the Company, while supporting the availability of committed funding. Importantly, the tranche-based structure is intended to allow the Company to manage shareholder dilution and regulatory thresholds while maintaining sufficient working capital to continue to execute its business plan.
Under the Facility, the Company may request the drawn down of funds (and Alumni will subscribe for Notes) in the following tranches: first tranche consisting of a principal amount of up to ¬£112,500 (First Tranche Notes), less fees and agreed deductions, second tranche consisting of a principal amount of up to ¬£625,000 (Second Tranche Notes) and subsequent tranches each consisting of a principal amount of up to ¬£200,000 (Subsequent Tranche Notes) subject to certain conditions being satisfied in each case.
The Directors believe that the net proceeds of the First Tranche Notes and the Second Tranche Notes (which together total ¬£737,500 principal gross) will enable the Group to continue in existence until late Q1 2026. Subsequent Tranche Notes may be capable of being drawn but there is no guarantee that this will happen. The Directors are in discussions regarding alternative sources of additional funding to extend the cash runway further, irrespective of the utilisation of the Notes. If Shareholders do not approve the Fundraise Resolutions, the Fundraise will not proceed, with the consequence that the Company would require alternative sources of funding and there can be no guarantee that the Company will be able to find such alternative sources of funding before late January 2026, or at all.
If the Fundraise is not capable of proceeding or if it is unsuccessful, it is highly likely that this will result in the Company and the Group not being a going concern and the Directors would be forced to take steps to place the Company into administration.
The Directors are of the view that the Fundraise represents the best and only realistic prospect for securing the financing required to meet the Company's working capital requirements and to support its commercialisation strategy.
The Directors were granted certain authorities to allot Ordinary Shares for cash and to disapply statutory pre-emption rights at the last annual general meeting of the Company held on 30 June 2025 (Existing Authorities). However, the Existing Authorities are insufficient for the size of the Fundraise and accordingly, the Company is calling the General Meeting, which has been convened for 20 January 2026, to (i) obtain new authorities to issue and allot new Ordinary Shares on a non-pre-emptive basis in respect of the Fundraise (Fundraise Authorities) and (ii) in addition to the Fundraise Authorities, obtain new allotment and dis-application of pre-emption rights authorities in a form similar to the Existing Authorities but calculated by reference to the anticipated Enlarged Share Capital (Standing Authorities).
The Fundraise Authorities would authorise the Directors to issue the Secured Convertible Loan Notes. However, the Directors believe it is in the interests of the Company for the Directors to be granted the Standing Authorities, to enable the Directors to take advantage of appropriate opportunities which may arise in the future.
The Fundraise is therefore conditional, inter alia, on the passing of the Fundraise Resolutions by Shareholders at the General Meeting, which is to be held at Shoosmiths LLP's London office at 1 Bow Churchyard, London, EC4M 9DQ at 9.30 a.m. on 20 January 2026.
Background, to and reasons for, the Fundraise and use of proceeds
Trellus Health¬Æ is a healthcare company providing innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Founded by Icahn School of Medicine at Mount Sinai faculty members Marla Dubinsky, MD and Laurie Keefer, PhD, globally recognised experts in treating the physical and emotional impacts of Inflammatory
B
owel Disease (IBD), with a combined 50 years of pioneering whole-person healthcare innovation.
The Company delivers Trellus Elevate¬Æ, a proprietary resilience-based digital platform that combines data analytics, with personalised scientifically proven resilience programs and value-based solutions to help people manage complex chronic conditions. Initially focused on costly gastrointestinal diseases such as IBD, where its methodology has demonstrated over 90% fewer hospitalisations and more than 70% fewer emergency room visits highlighting its role in improving outcomes while reducing healthcare costs
From its founding through 2024, the Company invested approximately $9.6 million in the development and enhancement of the Trellus Elevate¬Æ platform. The platform has been built to scale across multiple chronic conditions and therapeutic areas, integrate within complex and regulated healthcare environments, and support rapid commercial expansion while efficiently leveraging resilience team headcount.
Trellus Health's business model spans three key verticals: pharmaceutical patient support programs, clinical trial recruitment and retention solutions, and partnerships with US health plans. Through these channels, the Company seeks to improve outcomes, strengthen treatment adherence, and generate meaningful cost savings for healthcare stakeholders.
In early 2025, the Company signed a commercial-scale pilot with Johnson & Johnson Health Care Systems Inc. (J&J) to assess the potential for the Trellus Elevate¬Æ program to support patients with moderately to severely active IBD in the US. The program has delivered key early metrics, with 99% patient satisfaction ratings and an average of 50 engagement touchpoints over a 28-day period, supporting plans to broaden enrolment channels beyond the initial narrow funnel.
In the second quarter of 2025, the Company renewed its agreement with Pfizer to license patient support educational content for inclusion in Pfizer's IBD digital application. In parallel, Trellus Health
¬Æ
continues to support an ongoing Phase 2 IBD clinical trial through its licensing agreement with AstraZeneca.
In June 2025, Trellus Health
¬Æ
was granted preferred vendor status by a leading global contract research organisation (CRO). As announced on 22 October 2025, the Company subsequently signed a 12-month contract with this CRO to support recruitment and enrolment optimisation for an ongoing mid-stage clinical trial in immunology and inflammation. This program is being implemented on an ongoing basis.
Additionally, the Company has been granted preferred vendor status by a second leading global CRO and, as announced on 7 November 2025, signed a 12-month contract to support recruitment and enrolment optimisation for two late-stage clinical trials in immunology and inflammation. The program is also being implemented on an ongoing basis.
Together, these partnerships reinforce the value of Trellus Health's offering within the clinical trials vertical, provide access to underlying pharmaceutical clients, and accelerate contracting timelines.
The Company's strategy is increasingly focused on expanding its clinical trials business, addressing a well-defined and costly industry challenge. Industry data indicates that more than 50% of clinical trial participants fail screening, contributing to significant delays and inefficiencies in drug development. To address this gap, Trellus Health
¬Æ
has developed Trellus TrialSet‚Ñ¢, a solution designed to assess and strengthen participant readiness by ensuring individuals possess the resilience, skills, and tools required to engage, adhere, and persist throughout a trial, thereby optimising recruitment, enrolment, and retention.
Alongside these growth initiatives, the Company has taken additional cost-containment actions and reduced its average monthly cash burn from approximately $440,000 to $400,000 beginning in November 2025.
The Board is focused on driving commercial momentum and expanding the Company's footprint through strategic partnerships particularly within the pharmaceutical verticals. In order to achieve this, the Company requires further investment to extend its cash runway beyond January 2026, allowing time to secure additional commercial contracts. The Company expects that these contracts may take the form of either Pharma Patient Support Programmes (PSPs) or Clinical Trials (CTs) and, with an extended cash runway, is targeting up to 4 new CTs and up to 3 new PSPs, alongside a number of contract expansions over the next two years. Typically, PSPs have an illustrative contract value ranging in total between $500k and $1 million, whilst CTs have an illustrative contract value ranging in total between $150k and $500k excluding performance incentive fees.
To support the Company's commercialisation plans, the net proceeds of the Facility would be used by the Company for general working capital purposes, for commercial support and further expansion, technological advancements, specifically in regard to global data privacy (GDPR) and API/white labelling of the platform and intellectual property expansion specifically focused on PSP and CTs. As noted in the 24 November 2025 announcement mentioned above, the Company currently has funds through to the end of January 2026. The Fundraising is required to extend that runway and enable the Company to achieve its commercial objectives together with projected revenues from the new contracts and expansion agreements anticipated to be secured in 2025 and 2026.
Given the conversion price of the Notes is determined at the time of conversion notice by reference to a variable rate (as described in more detail at Details of the Fundraise below), the authorities to be granted by the Resolutions have been set at a high level to ensure that the Company has sufficient authorities to complete the Fundraising and such authorities, if granted at the General Meeting, will expire on the date falling 12 months after the passing of the Resolutions at the General Meeting which is to be held at 9.30 a.m. on 20 January 2026 at Shoosmiths LLP's London office at 1 Bow Churchyard, London, EC4M 9DQ.
Current Trading
The Company is in the early stages of commercialising its business and, as announced in its interim results on 8 September 2025, generated revenues of $295k in H1 2025 (H1 2024: $114k) and $379k from 1 January to 7 September 2025, related to implementation services and piloting new patients in the Trellus Health platform. The Company's adjusted EBITDA loss for the 6-month period to June 2025 was $2.6m (30 June 2024 $3.6m loss), in line with management expectations. Administrative costs for the first half were $3.3m (30 June 2024: $4.1m). At 30 June 2025, the Group had available cash resources of $1.6m (31 Dec. 2024: $4.3m), with the Company's average monthly burn decreased by an additional c.10% since 1 August 2025 to $440k per month.
As announced on 21 October 2025, the Company expects to reduce its average monthly cash burn from approximately $440,000 to around $395,000 going forward. On 24 November 2025, the Company announced that it has signed a $600,000 loan note with Mount Sinai, which extends the Company's runway to the end of January 2026. The Board is pleased with the ongoing commercial progress of the Company and looks forward to providing further updates during Q1 2026.
Details of the Fundraise
The Company proposes to enter into the Facility and related security agreement (
Debenture
) and warrant agreements (
Warrant Agreements
) with Alumni whereby the Company shall issue and Alumni shall subscribe for up to a maximum principal amount of ¬£5,000,000 Secured Convertible Loan Notes.
The Fundraise is conditional on the passing of the Fundraise Resolutions without material amendment at the General Meeting (or at any adjournment thereof) and the satisfaction of all conditions precedent in the Facility.
The key terms of the Facility are as follows:
1. the Company may request the drawn down of funds (and Alumni will subscribe for Notes) in the following tranches: first tranche consisting of a principal amount of up to ¬£112,500 (
First Tranche Notes
), less fees and agreed deductions, second tranche consisting of a principal amount of up to ¬£625,000 (
Second Tranche Notes
) and subsequent tranches each consisting of a principal amount of up to ¬£200,000 (
Subsequent Tranche Notes
) subject to certain conditions being satisfied in each case. The second tranche may only be drawn down at least 27 business days after closing of the first tranche, and the draw down of the subsequent tranches are conditional on the First Tranche Notes and the Second Tranche Notes being converted to shares. The conditions for each tranche can be waived at Alumni's discretion.
2. All
outstanding Notes plus interest will be repayable on the date 12 months from the date of the Facility subject to earlier repayment on the occurrence of market standard events of default or early termination of the Facility or voluntary prepayment(s). In the event of early termination of the Facility, the Company shall pay a 12% premium on any principal amounts (as defined in the Facility) previously drawn and outstanding that have not yet converted into equity.
3.
Interest will be payable on the outstanding amount of the Notes subscribed for at the rate of 2.5% per annum. The Company may elect to add such interest to the principal amount of the outstanding Notes.
4. The
Notes will be convertible at any time by written notice to the Company at a price per share in GBP equal to (all definitions in (a) - (c) below are as defined in the Facility):
(a) in
respect of the First Tranche Notes, interest on them and Premium Payment (if any), applicable to them, 0.75 multiplied by the lowest daily VWAP of the Shares on the five Trading Days immediately prior to the date of the conversion notice relating to such First Tranche Notes.
(b)
in respect of the Second Tranche Notes, interest on them and Premium Payment (if any), applicable to them, 0.55 multiplied by the lowest daily VWAP of the Shares on the five Trading Days immediately prior to the date of the conversion notice relating to such Second Tranche Notes; and
(c)
in respect of the Subsequent Tranche Notes (if any), interest on them and Premium Payment (if any), applicable to them, 0.75 multiplied by the lowest daily VWAP of the Shares on the five Trading Days immediately prior to the date of the conversion notice relating to such Subsequent Tranche Notes.
5.
The Notes will be secured by way of the Debenture, which will create fixed and floating charges over all present and future assets and undertaking of the Company subject to prior ranking security interests. The security will be granted in favour of a security trustee to hold the benefit of the security on trust for Alumni and Mount Sinai. Alumni and Mount Sinai will enter into an intercreditor arrangement pursuant to which their interests under the Secured Convertible Loan Note and the Mount Sinai Loan Note (having since been secured) respectively will rank pari passu (
Intercreditor Deed
). Draw down of the First Tranche Notes is conditional upon, inter alia, delivery to Alumni of the duly executed Debenture and Intercreditor Deed (both in a form acceptable to Alumni).
6.
With respect to the Warrant Agreements:
(a) each warrant granted pursuant to each Warrant Agreement (
Warrant
) will give its holder a right to subscribe for one Ordinary Share;
(b)
coverage will be 100 per cent of the nominal GBP value of each drawdown, save in relation to the second tranche whereby the coverage will be 130 per cent of the nominal GBP value of the drawdown;
(c) the exercise price will be 125 per cent of the mid-market price on the business day prior to the execution of the Facility and shall be adjusted upon any dilutive subsequent equity issuance (or equity-linked security) during the term of the relevant Warrant Agreement; and
(d) the exercise period in respect of each tranche of Warrants will be 4 years from grant.
Takeover Code
There is a limitation that prevents conversion of the Secured Convertible Loan Notes resulting in any shareholder holding over 29.9 per cent of the issued share capital of the Company.
The person responsible for arranging the release of this Announcement on behalf of the Company is Dr. Marla Dubinsky, Chief Executive Officer of the Company.
Expected Timetable of Principal Events
Announcement of the Fundraise
30 December 2025
Latest time and date for receipt of proxy votes for the General Meeting
9.30 a.m. on 16 January 2026
General Meeting
9.30 a.m. on 20 January 2026
Announcement of the results of the General Meeting
20 January 2026
Each of the times and dates above refer to London time and are subject to change. Certain of the events in the above timetable are conditional upon, inter alia, the passing of the Fundraise Resolutions to be proposed at the General Meeting. If any of the details contained in the timetable above should change, such change will be notified to shareholders by an announcement through a Regulatory Information¬†Service.
Enquiries:
Trellus Health plc
https://trellushealth.com/
Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder
Via Walbrook PR
Joy Bessenger, Chief Financial Officer
Singer Capital Markets (Nominated Adviser and Broker)
Philip Davies / James Todd / Patrick Weaver
Tel: +44 (0)20 7496 3000 303/
Walbrook PR
Tel: +44 (0)20 7933 8780 or
trellus@walbrookpr.com
Paul McManus / Lianne Applegarth /
Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303/
Alice Woodings
+44 (0)7407 804 654
About Trellus Health plc (
www.trellushealth.com
)
Trellus Health¬Æ (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.
Trellus Health¬Æ integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate¬Æ, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying the Trellus Elevate¬Æ methodology resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions and therapeutic areas, Trellus Health¬Æ considers its approach to have potential utility and demand across many conditions.
The Company also offers Trellus TrialSet‚Ñ¢, a solution for pharmaceutical partners spanning clinical trials to commercialisation, applying the same validated resilience science and platform to support trial success and long-term patient engagement
The Company was founded by Icahn School of Medicine at Mount Sinai faculty members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading experts in treating both the physical and emotional impacts of IBD, with a combined 50 years of pioneering whole-person healthcare innovation.
Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit:
www.trellushealth.com
APPENDIX I
DEFINITIONS
The following definitions apply
in the Appendices, and as
the context
shall admit, in the Announcement:
AIM
AIM, a
market operated by the London Stock Exchange;
AIM Rules
the AIM Rules for Companies published by the London Stock Exchange
;
Alumni:
Alumni Capital Limited;
Announcement
this Announcement
Board
the board of directors of the Company;
Business Day
a day (other than a Saturday or Sunday) on which commercial banks are open for general business in London, England;
Circular
the circular containing further details of the Fundraise and a notice convening the General Meeting in order to pass the Resolutions, which is expected to be published by the Company on or about 30 December
2025;
Company
or
Trellus Health
Trellus Health
plc;
CREST
the relevant system (as defined in the CREST Regulations) in
respect
of
which Euroclear is the Operator (as defined in the CREST Regulations);
CREST Regulations
the Uncertificated Securities Regulations 2001 (
S.I.
2001
No
3755)
(as amended);
Directors
or
Board
the current directors of the Company as at the date of this Announcement;
EEA
the European Economic Area;
Enlarged Share Capital
the entire issued share capital of the Company following assumed conversion of all the Secured Convertible Loan Notes issued to Alumni and exercise of the Warrant;
EU
the European Union;
Euroclear
Euroclear UK & International Limited, the
operator
of
CREST;
Existing Ordinary Shares
the 161,508,333
Ordinary Shares of
¬£0.0006 each
in issue at the date of this document, all of which are admitted to trading on AIM and being the entire issued ordinary share capital of the Company;
Facility
the secured convertible loan note instrument under which the Company proposes to constitute the Secured Convertible Loan Notes and issue them to Alumni;
FCA
the Financial Conduct Authority;
FSMA
the Financial Services and Markets Act 2000
,
as amended
;
Fundraise
means the raising of up to ¬£5 million by way of issue by the Company of the Secured Convertible Loan Notes;
Fundraise
Resolutions
resolutions 1 and 2 to be proposed at the General Meeting, as set out in the Notice of General Meeting;
Fundraise Shares
means the Ordinary Shares issued to Alumni following conversion of the Secured Convertible Loan Notes;
General Meeting
the general meeting of the Company convened for 9.30 a.m. on 20 January 2026 (or any adjournment thereof) at which the Resolutions will be proposed, notice of which is set out at the end of this document;
General
Resolutions
resolutions to be proposed at the General Meeting, further details of which are set out in the notice of General Meeting as contained in the Circular;
Group
the Company and its subsidiary undertakings (
and
"Group Company"
shall be construed accordingly
);
ISIN
International Securities Identification Number;
London Stock Exchange
London Stock Exchange plc;
MAR
Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse as it forms part of the law of England and Wales by virtue of section 3 of the European Union (Withdrawal) Act 2018 (as it may be modified from time to time by or under domestic law including, but not limited to, by the Market Abuse (Amendment) (EU Exit) Regulations 2019/310);
Material Adverse Effect
a material adverse effect, or any development or matter likely to have a material adverse effect, in or affecting the business, condition (financial, trading, operational, legal or otherwise), management, properties, assets, rights, results of operations, earnings or assets of the Group, whether or not arising in the ordinary course of business and whether or not foreseeable as at the date of the Placing Agreement;
Mount Sinai
Icahn School of Medicine at Mount Sinai;
Ordinary
Shares
ordinary
shares
of ¬£0.0006 each in the capital of the Company;
Post First Tranche Notes
the conversion of ¬£112,500 Secured Convertible Loan Notes into New Ordinary Shares;
Post Second Tranche Notes
the conversion of ¬£625,000 Secured Convertible Loan Notes into New Ordinary Shares;
Post Subsequent Tranche Notes
the conversion of ¬£200,000 Secured Convertible Loan Notes into New Ordinary Shares;
Resolutions
together
the General
Resolutions and the Fundraise Resolutions
;
RIS
shall have the same meaning as in the AIM Rules;
Secured Convertible Loan Notes or Notes
the secured convertible loan notes to be constituted by the Company pursuant to the Facility in the aggregate principal amount of ¬£5,000,000 plus any interest;
SCM Advisory
Singer Capital Markets Advisory LLP, the Company's nominated adviser;
Shareholders
holders of Ordinary Shares;
Singer Capital Markets
Singer Capital Markets Securities Limited, the Company's broker;
UK MAR
the Market Abuse Regulation (EU Regulation No. 596/2014 which forms part of domestic law pursuant to the European Union (Withdrawal) Act 2018);
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
MSCBLBDDLUXDGUG
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">2</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #2
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üìä</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Proposed issue of Secured Convertible Loan Notes</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">GROK: 90/100 ‚Ä¢ NEUTRAL</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    CORPORATE NEWS: Proposed issue of Secured Convertible Loan Notes | üìä Neutral informational update
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">30th Dec 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">5:00 pm</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                <div style="
                    margin: 16px 0;
                    padding: 14px;
                    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
                    border-radius: 10px;
                    border-left: 4px solid #3b82f6;
                ">
                    <h4 style="
                        font-size: 13px;
                        color: #1e293b;
                        margin-bottom: 12px;
                        font-weight: 700;
                        display: flex;
                        align-items: center;
                        gap: 8px;
                    ">
                        <span style="font-size: 16px;">ü§ñ</span> GROK INTELLIGENCE ANALYSIS
                        <span style="
                            display: inline-block;
                            background: #3b82f6;
                            color: white;
                            padding: 2px 8px;
                            border-radius: 10px;
                            font-size: 11px;
                            font-weight: 800;
                        ">90/100</span>
                    </h4>
                    
                    <div style="display: grid; gap: 10px;">
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">EVENT TYPE:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">CORPORATE NEWS: Proposed issue of Secured Convertible Loan Notes</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">TRADING VIEW:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üìä Neutral informational update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RISK LEVEL:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üîµ NEUTRAL: Balanced or routine update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RECOMMENDED:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">üìã HOLD: Monitor for developing patterns in announcements</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">COMPANY HEALTH:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">‚ö†Ô∏è CRITICAL: Serious company health concerns - potential distress signal</div>
                        </div>
                    </div>
                </div>
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Trading Days</td>
                    </tr>
                    
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">KEY METRICS:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">90%, 70%, 99%</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
30 Dec 2025 17:00
RNS Number : 1958N
Trellus Health PLC
30 December 2025
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO PURCHASE AND/OR SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN TRELLUS HEALTH PLC OR ANY OTHER ENTITY IN ANY JURISDICTION. NEITHER THIS ANNOUNCEMENT NOR THE FACT OF ITS DISTRIBUTION, SHALL FORM THE BASIS OF, OR BE RELIED ON IN CONNECTION WITH ANY INVESTMENT DECISION IN RESPECT OF TRELLUS HEALTH PLC OR ANY OTHER ENTITY.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION RELATING TO TRELLUS HEALTH PLC AND ITS SECURITIES FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (596/2014/EU) AS IT FORMS PART OF THE DOMESTIC LAW OF THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("EUWA") AND AS MODIFIED BY OR UNDER THE EUWA OR OTHER DOMESTIC LAW, INCLUDING BUT NOT LIMITED TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR), AS PERMITTED BY UK MAR. THIS INSIDE INFORMATION IS SET OUT IN THIS ANNOUNCEMENT. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION RELATING TO TRELLUS HEALTH PLC AND ITS SECURITIES, WHICH IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Trellus Health plc
("
Trellus Health
" or the "
Company
")
Proposed issue of Secured Convertible Loan Notes to raise up to ¬£5 million
and grant of Warrants
Definitions contained within Appendix I to this Announcement apply, unless the context requires otherwise
Trellus Health plc (AIM: TRLS), a healthcare company delivering Trellus Elevate¬Æ, a digital platform that integrates data analytics with personalised, scientifically proven resilience programs and value-based solutions to manage complex chronic conditions, announces that it proposes to issue ¬£5 million Secured Convertible Loan Notes (the Facility) to an institutional investor to extend the Company's cash runway, subject to Shareholder approval. The Company had previously announced that it had entered into an unsecured loan agreement with its long-standing substantial shareholder, Mount Sinai, with a principal amount of US$600,000 which
supported the continued execution of the Company's commercial strategy and extend its near-term cash runway to late January 2026. Since this time, the Company has been in active discussions with the aim of securing additional funds to extend the cash runway further, hence the
Secured Convertible Loan Notes.
The Facility is structured to provide Trellus Health with flexible, staged access to capital to support its operational and commercial objectives, while managing dilution and aligning funding availability with execution milestones.
Key features include:
¬∑
12 month facility of up to ¬£5 million in principal, available in multiple tranches;
¬∑
conversion at a discount to market price at the time of conversion, with tranche-specific terms; and
¬∑
warrant coverage issued in connection with each tranche.
Further details of the Facility are set out below and in the Circular, which is to be posted to Shareholders tomorrow and will be made available on the Company's website at
trellushealth.com/investors
.
The Board believes that the Facility:
¬∑
strengthens the Company's near-term funding position while preserving flexibility over the timing and scale of capital drawdowns;
¬∑
enables the Company to align conversions with market conditions;
¬∑
supports the Company's ongoing commercial initiatives and partnership discussions; and
¬∑
reflects continued access to institutional capital from a financial investor familiar with structured growth financing.
The Directors also consider the inclusion of warrant coverage (details of which are provided below) provides additional alignment between investor returns and the longer-term performance of the Company, while supporting the availability of committed funding. Importantly, the tranche-based structure is intended to allow the Company to manage shareholder dilution and regulatory thresholds while maintaining sufficient working capital to continue to execute its business plan.
Under the Facility, the Company may request the drawn down of funds (and Alumni will subscribe for Notes) in the following tranches: first tranche consisting of a principal amount of up to ¬£112,500 (First Tranche Notes), less fees and agreed deductions, second tranche consisting of a principal amount of up to ¬£625,000 (Second Tranche Notes) and subsequent tranches each consisting of a principal amount of up to ¬£200,000 (Subsequent Tranche Notes) subject to certain conditions being satisfied in each case.
The Directors believe that the net proceeds of the First Tranche Notes and the Second Tranche Notes (which together total ¬£737,500 principal gross) will enable the Group to continue in existence until late Q1 2026. Subsequent Tranche Notes may be capable of being drawn but there is no guarantee that this will happen. The Directors are in discussions regarding alternative sources of additional funding to extend the cash runway further, irrespective of the utilisation of the Notes. If Shareholders do not approve the Fundraise Resolutions, the Fundraise will not proceed, with the consequence that the Company would require alternative sources of funding and there can be no guarantee that the Company will be able to find such alternative sources of funding before late January 2026, or at all.
If the Fundraise is not capable of proceeding or if it is unsuccessful, it is highly likely that this will result in the Company and the Group not being a going concern and the Directors would be forced to take steps to place the Company into administration.
The Directors are of the view that the Fundraise represents the best and only realistic prospect for securing the financing required to meet the Company's working capital requirements and to support its commercialisation strategy.
The Directors were granted certain authorities to allot Ordinary Shares for cash and to disapply statutory pre-emption rights at the last annual general meeting of the Company held on 30 June 2025 (Existing Authorities). However, the Existing Authorities are insufficient for the size of the Fundraise and accordingly, the Company is calling the General Meeting, which has been convened for 20 January 2026, to (i) obtain new authorities to issue and allot new Ordinary Shares on a non-pre-emptive basis in respect of the Fundraise (Fundraise Authorities) and (ii) in addition to the Fundraise Authorities, obtain new allotment and dis-application of pre-emption rights authorities in a form similar to the Existing Authorities but calculated by reference to the anticipated Enlarged Share Capital (Standing Authorities).
The Fundraise Authorities would authorise the Directors to issue the Secured Convertible Loan Notes. However, the Directors believe it is in the interests of the Company for the Directors to be granted the Standing Authorities, to enable the Directors to take advantage of appropriate opportunities which may arise in the future.
The Fundraise is therefore conditional, inter alia, on the passing of the Fundraise Resolutions by Shareholders at the General Meeting, which is to be held at Shoosmiths LLP's London office at 1 Bow Churchyard, London, EC4M 9DQ at 9.30 a.m. on 20 January 2026.
Background, to and reasons for, the Fundraise and use of proceeds
Trellus Health¬Æ is a healthcare company providing innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Founded by Icahn School of Medicine at Mount Sinai faculty members Marla Dubinsky, MD and Laurie Keefer, PhD, globally recognised experts in treating the physical and emotional impacts of Inflammatory
B
owel Disease (IBD), with a combined 50 years of pioneering whole-person healthcare innovation.
The Company delivers Trellus Elevate¬Æ, a proprietary resilience-based digital platform that combines data analytics, with personalised scientifically proven resilience programs and value-based solutions to help people manage complex chronic conditions. Initially focused on costly gastrointestinal diseases such as IBD, where its methodology has demonstrated over 90% fewer hospitalisations and more than 70% fewer emergency room visits highlighting its role in improving outcomes while reducing healthcare costs
From its founding through 2024, the Company invested approximately $9.6 million in the development and enhancement of the Trellus Elevate¬Æ platform. The platform has been built to scale across multiple chronic conditions and therapeutic areas, integrate within complex and regulated healthcare environments, and support rapid commercial expansion while efficiently leveraging resilience team headcount.
Trellus Health's business model spans three key verticals: pharmaceutical patient support programs, clinical trial recruitment and retention solutions, and partnerships with US health plans. Through these channels, the Company seeks to improve outcomes, strengthen treatment adherence, and generate meaningful cost savings for healthcare stakeholders.
In early 2025, the Company signed a commercial-scale pilot with Johnson & Johnson Health Care Systems Inc. (J&J) to assess the potential for the Trellus Elevate¬Æ program to support patients with moderately to severely active IBD in the US. The program has delivered key early metrics, with 99% patient satisfaction ratings and an average of 50 engagement touchpoints over a 28-day period, supporting plans to broaden enrolment channels beyond the initial narrow funnel.
In the second quarter of 2025, the Company renewed its agreement with Pfizer to license patient support educational content for inclusion in Pfizer's IBD digital application. In parallel, Trellus Health
¬Æ
continues to support an ongoing Phase 2 IBD clinical trial through its licensing agreement with AstraZeneca.
In June 2025, Trellus Health
¬Æ
was granted preferred vendor status by a leading global contract research organisation (CRO). As announced on 22 October 2025, the Company subsequently signed a 12-month contract with this CRO to support recruitment and enrolment optimisation for an ongoing mid-stage clinical trial in immunology and inflammation. This program is being implemented on an ongoing basis.
Additionally, the Company has been granted preferred vendor status by a second leading global CRO and, as announced on 7 November 2025, signed a 12-month contract to support recruitment and enrolment optimisation for two late-stage clinical trials in immunology and inflammation. The program is also being implemented on an ongoing basis.
Together, these partnerships reinforce the value of Trellus Health's offering within the clinical trials vertical, provide access to underlying pharmaceutical clients, and accelerate contracting timelines.
The Company's strategy is increasingly focused on expanding its clinical trials business, addressing a well-defined and costly industry challenge. Industry data indicates that more than 50% of clinical trial participants fail screening, contributing to significant delays and inefficiencies in drug development. To address this gap, Trellus Health
¬Æ
has developed Trellus TrialSet‚Ñ¢, a solution designed to assess and strengthen participant readiness by ensuring individuals possess the resilience, skills, and tools required to engage, adhere, and persist throughout a trial, thereby optimising recruitment, enrolment, and retention.
Alongside these growth initiatives, the Company has taken additional cost-containment actions and reduced its average monthly cash burn from approximately $440,000 to $400,000 beginning in November 2025.
The Board is focused on driving commercial momentum and expanding the Company's footprint through strategic partnerships particularly within the pharmaceutical verticals. In order to achieve this, the Company requires further investment to extend its cash runway beyond January 2026, allowing time to secure additional commercial contracts. The Company expects that these contracts may take the form of either Pharma Patient Support Programmes (PSPs) or Clinical Trials (CTs) and, with an extended cash runway, is targeting up to 4 new CTs and up to 3 new PSPs, alongside a number of contract expansions over the next two years. Typically, PSPs have an illustrative contract value ranging in total between $500k and $1 million, whilst CTs have an illustrative contract value ranging in total between $150k and $500k excluding performance incentive fees.
To support the Company's commercialisation plans, the net proceeds of the Facility would be used by the Company for general working capital purposes, for commercial support and further expansion, technological advancements, specifically in regard to global data privacy (GDPR) and API/white labelling of the platform and intellectual property expansion specifically focused on PSP and CTs. As noted in the 24 November 2025 announcement mentioned above, the Company currently has funds through to the end of January 2026. The Fundraising is required to extend that runway and enable the Company to achieve its commercial objectives together with projected revenues from the new contracts and expansion agreements anticipated to be secured in 2025 and 2026.
Given the conversion price of the Notes is determined at the time of conversion notice by reference to a variable rate (as described in more detail at Details of the Fundraise below), the authorities to be granted by the Resolutions have been set at a high level to ensure that the Company has sufficient authorities to complete the Fundraising and such authorities, if granted at the General Meeting, will expire on the date falling 12 months after the passing of the Resolutions at the General Meeting which is to be held at 9.30 a.m. on 20 January 2026 at Shoosmiths LLP's London office at 1 Bow Churchyard, London, EC4M 9DQ.
Current Trading
The Company is in the early stages of commercialising its business and, as announced in its interim results on 8 September 2025, generated revenues of $295k in H1 2025 (H1 2024: $114k) and $379k from 1 January to 7 September 2025, related to implementation services and piloting new patients in the Trellus Health platform. The Company's adjusted EBITDA loss for the 6-month period to June 2025 was $2.6m (30 June 2024 $3.6m loss), in line with management expectations. Administrative costs for the first half were $3.3m (30 June 2024: $4.1m). At 30 June 2025, the Group had available cash resources of $1.6m (31 Dec. 2024: $4.3m), with the Company's average monthly burn decreased by an additional c.10% since 1 August 2025 to $440k per month.
As announced on 21 October 2025, the Company expects to reduce its average monthly cash burn from approximately $440,000 to around $395,000 going forward. On 24 November 2025, the Company announced that it has signed a $600,000 loan note with Mount Sinai, which extends the Company's runway to the end of January 2026. The Board is pleased with the ongoing commercial progress of the Company and looks forward to providing further updates during Q1 2026.
Details of the Fundraise
The Company proposes to enter into the Facility and related security agreement (
Debenture
) and warrant agreements (
Warrant Agreements
) with Alumni whereby the Company shall issue and Alumni shall subscribe for up to a maximum principal amount of ¬£5,000,000 Secured Convertible Loan Notes.
The Fundraise is conditional on the passing of the Fundraise Resolutions without material amendment at the General Meeting (or at any adjournment thereof) and the satisfaction of all conditions precedent in the Facility.
The key terms of the Facility are as follows:
1. the Company may request the drawn down of funds (and Alumni will subscribe for Notes) in the following tranches: first tranche consisting of a principal amount of up to ¬£112,500 (
First Tranche Notes
), less fees and agreed deductions, second tranche consisting of a principal amount of up to ¬£625,000 (
Second Tranche Notes
) and subsequent tranches each consisting of a principal amount of up to ¬£200,000 (
Subsequent Tranche Notes
) subject to certain conditions being satisfied in each case. The second tranche may only be drawn down at least 27 business days after closing of the first tranche, and the draw down of the subsequent tranches are conditional on the First Tranche Notes and the Second Tranche Notes being converted to shares. The conditions for each tranche can be waived at Alumni's discretion.
2. All
outstanding Notes plus interest will be repayable on the date 12 months from the date of the Facility subject to earlier repayment on the occurrence of market standard events of default or early termination of the Facility or voluntary prepayment(s). In the event of early termination of the Facility, the Company shall pay a 12% premium on any principal amounts (as defined in the Facility) previously drawn and outstanding that have not yet converted into equity.
3.
Interest will be payable on the outstanding amount of the Notes subscribed for at the rate of 2.5% per annum. The Company may elect to add such interest to the principal amount of the outstanding Notes.
4. The
Notes will be convertible at any time by written notice to the Company at a price per share in GBP equal to (all definitions in (a) - (c) below are as defined in the Facility):
(a) in
respect of the First Tranche Notes, interest on them and Premium Payment (if any), applicable to them, 0.75 multiplied by the lowest daily VWAP of the Shares on the five Trading Days immediately prior to the date of the conversion notice relating to such First Tranche Notes.
(b)
in respect of the Second Tranche Notes, interest on them and Premium Payment (if any), applicable to them, 0.55 multiplied by the lowest daily VWAP of the Shares on the five Trading Days immediately prior to the date of the conversion notice relating to such Second Tranche Notes; and
(c)
in respect of the Subsequent Tranche Notes (if any), interest on them and Premium Payment (if any), applicable to them, 0.75 multiplied by the lowest daily VWAP of the Shares on the five Trading Days immediately prior to the date of the conversion notice relating to such Subsequent Tranche Notes.
5.
The Notes will be secured by way of the Debenture, which will create fixed and floating charges over all present and future assets and undertaking of the Company subject to prior ranking security interests. The security will be granted in favour of a security trustee to hold the benefit of the security on trust for Alumni and Mount Sinai. Alumni and Mount Sinai will enter into an intercreditor arrangement pursuant to which their interests under the Secured Convertible Loan Note and the Mount Sinai Loan Note (having since been secured) respectively will rank pari passu (
Intercreditor Deed
). Draw down of the First Tranche Notes is conditional upon, inter alia, delivery to Alumni of the duly executed Debenture and Intercreditor Deed (both in a form acceptable to Alumni).
6.
With respect to the Warrant Agreements:
(a) each warrant granted pursuant to each Warrant Agreement (
Warrant
) will give its holder a right to subscribe for one Ordinary Share;
(b)
coverage will be 100 per cent of the nominal GBP value of each drawdown, save in relation to the second tranche whereby the coverage will be 130 per cent of the nominal GBP value of the drawdown;
(c) the exercise price will be 125 per cent of the mid-market price on the business day prior to the execution of the Facility and shall be adjusted upon any dilutive subsequent equity issuance (or equity-linked security) during the term of the relevant Warrant Agreement; and
(d) the exercise period in respect of each tranche of Warrants will be 4 years from grant.
Takeover Code
There is a limitation that prevents conversion of the Secured Convertible Loan Notes resulting in any shareholder holding over 29.9 per cent of the issued share capital of the Company.
The person responsible for arranging the release of this Announcement on behalf of the Company is Dr. Marla Dubinsky, Chief Executive Officer of the Company.
Expected Timetable of Principal Events
Announcement of the Fundraise
30 December 2025
Latest time and date for receipt of proxy votes for the General Meeting
9.30 a.m. on 16 January 2026
General Meeting
9.30 a.m. on 20 January 2026
Announcement of the results of the General Meeting
20 January 2026
Each of the times and dates above refer to London time and are subject to change. Certain of the events in the above timetable are conditional upon, inter alia, the passing of the Fundraise Resolutions to be proposed at the General Meeting. If any of the details contained in the timetable above should change, such change will be notified to shareholders by an announcement through a Regulatory Information¬†Service.
Enquiries:
Trellus Health plc
https://trellushealth.com/
Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder
Via Walbrook PR
Joy Bessenger, Chief Financial Officer
Singer Capital Markets (Nominated Adviser and Broker)
Philip Davies / James Todd / Patrick Weaver
Tel: +44 (0)20 7496 3000 303/
Walbrook PR
Tel: +44 (0)20 7933 8780 or
trellus@walbrookpr.com
Paul McManus / Lianne Applegarth /
Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303/
Alice Woodings
+44 (0)7407 804 654
About Trellus Health plc (
www.trellushealth.com
)
Trellus Health¬Æ (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.
Trellus Health¬Æ integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate¬Æ, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying the Trellus Elevate¬Æ methodology resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions and therapeutic areas, Trellus Health¬Æ considers its approach to have potential utility and demand across many conditions.
The Company also offers Trellus TrialSet‚Ñ¢, a solution for pharmaceutical partners spanning clinical trials to commercialisation, applying the same validated resilience science and platform to support trial success and long-term patient engagement
The Company was founded by Icahn School of Medicine at Mount Sinai faculty members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading experts in treating both the physical and emotional impacts of IBD, with a combined 50 years of pioneering whole-person healthcare innovation.
Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit:
www.trellushealth.com
APPENDIX I
DEFINITIONS
The following definitions apply
in the Appendices, and as
the context
shall admit, in the Announcement:
AIM
AIM, a
market operated by the London Stock Exchange;
AIM Rules
the AIM Rules for Companies published by the London Stock Exchange
;
Alumni:
Alumni Capital Limited;
Announcement
this Announcement
Board
the board of directors of the Company;
Business Day
a day (other than a Saturday or Sunday) on which commercial banks are open for general business in London, England;
Circular
the circular containing further details of the Fundraise and a notice convening the General Meeting in order to pass the Resolutions, which is expected to be published by the Company on or about 30 December
2025;
Company
or
Trellus Health
Trellus Health
plc;
CREST
the relevant system (as defined in the CREST Regulations) in
respect
of
which Euroclear is the Operator (as defined in the CREST Regulations);
CREST Regulations
the Uncertificated Securities Regulations 2001 (
S.I.
2001
No
3755)
(as amended);
Directors
or
Board
the current directors of the Company as at the date of this Announcement;
EEA
the European Economic Area;
Enlarged Share Capital
the entire issued share capital of the Company following assumed conversion of all the Secured Convertible Loan Notes issued to Alumni and exercise of the Warrant;
EU
the European Union;
Euroclear
Euroclear UK & International Limited, the
operator
of
CREST;
Existing Ordinary Shares
the 161,508,333
Ordinary Shares of
¬£0.0006 each
in issue at the date of this document, all of which are admitted to trading on AIM and being the entire issued ordinary share capital of the Company;
Facility
the secured convertible loan note instrument under which the Company proposes to constitute the Secured Convertible Loan Notes and issue them to Alumni;
FCA
the Financial Conduct Authority;
FSMA
the Financial Services and Markets Act 2000
,
as amended
;
Fundraise
means the raising of up to ¬£5 million by way of issue by the Company of the Secured Convertible Loan Notes;
Fundraise
Resolutions
resolutions 1 and 2 to be proposed at the General Meeting, as set out in the Notice of General Meeting;
Fundraise Shares
means the Ordinary Shares issued to Alumni following conversion of the Secured Convertible Loan Notes;
General Meeting
the general meeting of the Company convened for 9.30 a.m. on 20 January 2026 (or any adjournment thereof) at which the Resolutions will be proposed, notice of which is set out at the end of this document;
General
Resolutions
resolutions to be proposed at the General Meeting, further details of which are set out in the notice of General Meeting as contained in the Circular;
Group
the Company and its subsidiary undertakings (
and
"Group Company"
shall be construed accordingly
);
ISIN
International Securities Identification Number;
London Stock Exchange
London Stock Exchange plc;
MAR
Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse as it forms part of the law of England and Wales by virtue of section 3 of the European Union (Withdrawal) Act 2018 (as it may be modified from time to time by or under domestic law including, but not limited to, by the Market Abuse (Amendment) (EU Exit) Regulations 2019/310);
Material Adverse Effect
a material adverse effect, or any development or matter likely to have a material adverse effect, in or affecting the business, condition (financial, trading, operational, legal or otherwise), management, properties, assets, rights, results of operations, earnings or assets of the Group, whether or not arising in the ordinary course of business and whether or not foreseeable as at the date of the Placing Agreement;
Mount Sinai
Icahn School of Medicine at Mount Sinai;
Ordinary
Shares
ordinary
shares
of ¬£0.0006 each in the capital of the Company;
Post First Tranche Notes
the conversion of ¬£112,500 Secured Convertible Loan Notes into New Ordinary Shares;
Post Second Tranche Notes
the conversion of ¬£625,000 Secured Convertible Loan Notes into New Ordinary Shares;
Post Subsequent Tranche Notes
the conversion of ¬£200,000 Secured Convertible Loan Notes into New Ordinary Shares;
Resolutions
together
the General
Resolutions and the Fundraise Resolutions
;
RIS
shall have the same meaning as in the AIM Rules;
Secured Convertible Loan Notes or Notes
the secured convertible loan notes to be constituted by the Company pursuant to the Facility in the aggregate principal amount of ¬£5,000,000 plus any interest;
SCM Advisory
Singer Capital Markets Advisory LLP, the Company's nominated adviser;
Shareholders
holders of Ordinary Shares;
Singer Capital Markets
Singer Capital Markets Securities Limited, the Company's broker;
UK MAR
the Market Abuse Regulation (EU Regulation No. 596/2014 which forms part of domestic law pursuant to the European Union (Withdrawal) Act 2018);
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
MSCBLBDDLUXDGUG
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">3</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #3
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üìä</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Finance update</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">GROK: 75/100 ‚Ä¢ NEUTRAL</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    CORPORATE NEWS: Finance update | üìä Neutral informational update
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">24th Nov 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7:00 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                <div style="
                    margin: 16px 0;
                    padding: 14px;
                    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
                    border-radius: 10px;
                    border-left: 4px solid #3b82f6;
                ">
                    <h4 style="
                        font-size: 13px;
                        color: #1e293b;
                        margin-bottom: 12px;
                        font-weight: 700;
                        display: flex;
                        align-items: center;
                        gap: 8px;
                    ">
                        <span style="font-size: 16px;">ü§ñ</span> GROK INTELLIGENCE ANALYSIS
                        <span style="
                            display: inline-block;
                            background: #3b82f6;
                            color: white;
                            padding: 2px 8px;
                            border-radius: 10px;
                            font-size: 11px;
                            font-weight: 800;
                        ">75/100</span>
                    </h4>
                    
                    <div style="display: grid; gap: 10px;">
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">EVENT TYPE:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">CORPORATE NEWS: Finance update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">TRADING VIEW:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üìä Neutral informational update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RISK LEVEL:</div>
                            <div style="font-size: 12px; color: #10b981; font-weight: 600;">üü¢ LOW RISK: Positive signals, minimal concerns</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RECOMMENDED:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">üìã HOLD: Monitor for developing patterns in announcements</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">COMPANY HEALTH:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">üìà IMPROVING: Company demonstrating strength and growth</div>
                        </div>
                    </div>
                </div>
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Ordinary Shares</td>
                    </tr>
                    
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">KEY METRICS:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">8%, 29.9%, 25.0%</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
24 Nov 2025 07:00
RNS Number : 6315I
Trellus Health PLC
24 November 2025
This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310.¬†Upon the publication of this announcement, this inside information is now considered to be in the public domain.
Trellus Health plc
("Trellus Health", the "Company" or the "Group")
Finance update
LONDON, U.K. AND NEW YORK, U.S. (24
November 2025)
. Trellus Health¬Æ plc (AIM: TRLS), a healthcare company delivering Trellus Elevate¬Æ, a digital platform that integrates data analytics with personalised, scientifically proven resilience programs and value-based solutions to manage complex chronic conditions, announces it has entered into a unsecured loan agreement with the Company's long standing substantial shareholder, Icahn School of Medicine at Mount Sinai ("
Mount Sinai
"), with a principal amount of US$600,000 (the "
Loan Note
").
Loan Note Terms
The Loan Note will be non-interest bearing for the first six months. Thereafter, it will accrue interest at an annual rate of 8%, payable in either new ordinary shares of 0.06 pence each ("
Ordinary Shares
") or cash, at the Company's discretion, upon conversion of the principal amount of the Loan Note.
The term of the Loan Note is 12 months, at which point the Company may elect to redeem, convert into Ordinary Shares, or apply a combination of both at a conversion price of 0.525 pence, being the 5-day mid-market price of the Company's shares ending on the business day prior to signing the Loan Note.
Under the terms of the Loan Note, any conversion into Ordinary Shares is subject to a cap preventing Mount Sinai from holding more than 29.9% of the Company's issued share capital. This restriction applies to both the principal and any accrued interest.
Cash Runway
The proceeds from the Loan Note will support the continued execution of the Company's commercial strategy and extend its near-term cash runway to late January 2026. The Company remains in active discussions regarding a potential equity fundraising to extend the cash runway further. While these discussions are at an advanced stage, there is no guarantee that they will be concluded successfully or within the required timeframe.
The Company continues to focus on securing additional commercial contracts with pharmaceutical companies and Contract Research Organizations ("
CROs
"). Illustrative contract values typically range in total between $500k and $1 million for pharma and between $150k and $500k for CROs, excluding performance incentive fees.
Related Party Transaction
The Loan Note is deemed to be related party transaction under AIM Rule 13 of the AIM Rules for Companies. Mount Sinai is a substantial shareholder holding 40,384,897 Ordinary Shares equal to 25.0% of the issued share capital of the Company. The Company's Directors (excluding those who are connected to Mount Sinai) consider, having consulted with the Nominated Adviser,¬†Singer Capital Markets, that the terms of the related party transaction are fair and reasonable insofar as the shareholders of the Company are concerned.
Dr. Marla Dubinsky, Chief Executive Officer of Trellus Health, said:
"
We are extremely grateful for Mount Sinai's continued support, which enables us to focus on executing agreements with pharmaceutical companies and CROs. Over the past month, we have signed contracts with two leading global CROs, reaffirming both the value of our offering to the pharmaceutical sector and our ability to secure and deliver on partnerships with industry leaders in drug development and clinical research. We have already begun implementation for the Phase 2B and Phase 3 trials with these partners and expect to launch the initial TrialSet‚Ñ¢ programs by year-end."
Enquiries:
Trellus Health plc
https://trellushealth.com/
Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder
Via Walbrook PR
Joy Bessenger, Chief Financial Officer
Singer Capital Markets
Phil Davies / Patrick Weaver
Tel: +44 (0)20 7496 3000
Walbrook PR
Tel: +44 (0)20 7933 8780 or
trellus@walbrookpr.com
Paul McManus / Lianne Applegarth /
Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303/
Alice Woodings
+44 (0)7407 804 654
About Trellus Health plc (www.trellushealth.com)
Trellus Health¬Æ (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.
Trellus Health¬Æ integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate¬Æ, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying the Trellus Elevate¬Æ methodology resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions and therapeutic areas, Trellus Health¬Æ considers its approach to have potential utility and demand across many conditions.
The Company also offers Trellus TrialSet‚Ñ¢, a solution for pharmaceutical partners spanning clinical trials to commercialisation, applying the same validated resilience science and platform to support trial success and long-term patient engagement
The Company was founded by Icahn School of Medicine at Mount Sinai faculty members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading experts in treating both the physical and emotional impacts of IBD, with a combined 50 years of pioneering whole-person healthcare innovation. Both the founders continue to have a financial interest in the Company.
Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit:
www.trellushealth.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
UPDPKNBBKBDBODB
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">4</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #4
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üìä</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Contract signed with second leading CRO</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">GROK: 70/100 ‚Ä¢ NEUTRAL</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    BUSINESS WIN: Contract won or partnership announced | üìä Neutral informational update
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7th Nov 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7:00 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                <div style="
                    margin: 16px 0;
                    padding: 14px;
                    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
                    border-radius: 10px;
                    border-left: 4px solid #3b82f6;
                ">
                    <h4 style="
                        font-size: 13px;
                        color: #1e293b;
                        margin-bottom: 12px;
                        font-weight: 700;
                        display: flex;
                        align-items: center;
                        gap: 8px;
                    ">
                        <span style="font-size: 16px;">ü§ñ</span> GROK INTELLIGENCE ANALYSIS
                        <span style="
                            display: inline-block;
                            background: #3b82f6;
                            color: white;
                            padding: 2px 8px;
                            border-radius: 10px;
                            font-size: 11px;
                            font-weight: 800;
                        ">70/100</span>
                    </h4>
                    
                    <div style="display: grid; gap: 10px;">
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">EVENT TYPE:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">BUSINESS WIN: Contract won or partnership announced</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">TRADING VIEW:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üìä Neutral informational update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RISK LEVEL:</div>
                            <div style="font-size: 12px; color: #10b981; font-weight: 600;">üü¢ LOW RISK: Positive signals, minimal concerns</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RECOMMENDED:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">üìã HOLD: Monitor for developing patterns in announcements</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">COMPANY HEALTH:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">üìà IMPROVING: Company demonstrating strength and growth</div>
                        </div>
                    </div>
                </div>
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Jen Boorer</td>
                    </tr>
                    
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">KEY METRICS:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">90%, 70%</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
7 Nov 2025 07:00
RNS Number : 5733G
Trellus Health PLC
07 November 2025
Trellus Health plc
("Trellus Health", the "Company" or the "Group")
Contract signed with second leading CRO
LONDON, U.K. AND NEW YORK, U.S. (07 November 2025)
. Trellus Health¬Æ plc (AIM: TRLS), a healthcare company delivering Trellus Elevate¬Æ, a digital platform that integrates data analytics with personalised, scientifically proven resilience programs and value-based solutions to manage complex chronic conditions, announces it has signed a 12 month contract (the "Contract") with one of the largest global clinical research organisations ('CRO's') to utilise its Trellus TrialSet‚Ñ¢ offering. The Contract is due to commence before year end, and will focus on immunology and inflammation, supporting recruitment and enrolment optimisation for two late-stage clinical trials.
This marks the Company's second contract with a leading CRO, further reinforcing the clinical trials sector as a strategic growth area for Trellus Health
¬Æ
. The Trellus TrialSet‚Ñ¢ program is designed to enhance clinical trial recruitment by identifying individuals with lower resilience who may be hesitant to enrol and providing structured, evidence-based support to strengthen their resilience and readiness for participation.
The Contract, which includes an upfront fee, a monthly management fee, and milestone payments, is structured around three key performance indicators: (i) the number of potential eligible participants opting into the Trellus TrialSet‚Ñ¢ program, (ii) the increase in qualified participants referred for screening, and (iii) the reduction in the screen failure rate.
Dr. Marla Dubinsky, Chief Executive Officer of Trellus Health, said:
"This represents another important milestone for Trellus Health¬Æ, underscoring the intrinsic value of our Trellus TrialSet‚Ñ¢ digital solution and reflecting our continued focus on strategic execution. Since its launch earlier this summer, we have entered into two agreements with leading CROs, validating the relevance and differentiation of our offering. While the contract does not immediately extend the Company's current cash runway beyond early December 2025,¬†combined with the Patient Support Program agreement signed with Johnson & Johnson in January 2025 which launched in the spring, these milestones demonstrate the growing recognition of the value Trellus Health delivers to the pharmaceutical sector.
"The Company continues to explore options for a potential equity fundraising¬†and further updates will be provided in due course, as appropriate."
Regulatory Information
This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310.¬†Upon the publication of this announcement, this inside information is now considered to be in the public domain.
Enquiries:
Trellus Health plc
https://trellushealth.com/
Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder
Via Walbrook PR
Joy Bessenger, Chief Financial Officer
Singer Capital Markets
Jen Boorer / James Todd / Patrick Weaver
Tel: +44 (0)20 7496 3000
Walbrook PR
Tel: +44 (0)20 7933 8780 or
trellus@walbrookpr.com
Paul McManus / Lianne Applegarth /
Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303/
Alice Woodings
+44 (0)7407 804 654
About Trellus Health plc (www.trellushealth.com)
Trellus Health¬Æ (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.
Trellus Health¬Æ integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate¬Æ, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying the Trellus Elevate¬Æ methodology resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions and therapeutic areas, Trellus Health¬Æ considers its approach to have potential utility and demand across many conditions.
The Company also offers Trellus TrialSet‚Ñ¢, a solution for pharmaceutical partners spanning clinical trials to commercialisation, applying the same validated resilience science and platform to support trial success and long-term patient engagement
The Company was founded by Icahn School of Medicine at Mount Sinai faculty members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading experts in treating both the physical and emotional impacts of IBD, with a combined 50 years of pioneering whole-person healthcare innovation.
Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit:
www.trellushealth.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
CNTUPGWWGUPAGMQ
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">5</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #5
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üìä</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Contract Signed with Leading Global CRO</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">GROK: 70/100 ‚Ä¢ NEUTRAL</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    BUSINESS WIN: Contract won or partnership announced | üìä Neutral informational update
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">22nd Oct 2025</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7:00 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                <div style="
                    margin: 16px 0;
                    padding: 14px;
                    background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
                    border-radius: 10px;
                    border-left: 4px solid #3b82f6;
                ">
                    <h4 style="
                        font-size: 13px;
                        color: #1e293b;
                        margin-bottom: 12px;
                        font-weight: 700;
                        display: flex;
                        align-items: center;
                        gap: 8px;
                    ">
                        <span style="font-size: 16px;">ü§ñ</span> GROK INTELLIGENCE ANALYSIS
                        <span style="
                            display: inline-block;
                            background: #3b82f6;
                            color: white;
                            padding: 2px 8px;
                            border-radius: 10px;
                            font-size: 11px;
                            font-weight: 800;
                        ">70/100</span>
                    </h4>
                    
                    <div style="display: grid; gap: 10px;">
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">EVENT TYPE:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">BUSINESS WIN: Contract won or partnership announced</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">TRADING VIEW:</div>
                            <div style="font-size: 12px; color: #3b82f6; font-weight: 600;">üìä Neutral informational update</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RISK LEVEL:</div>
                            <div style="font-size: 12px; color: #10b981; font-weight: 600;">üü¢ LOW RISK: Positive signals, minimal concerns</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">RECOMMENDED:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">üìã HOLD: Monitor for developing patterns in announcements</div>
                        </div>
                        
                        <div style="display: grid; grid-template-columns: 140px 1fr; gap: 8px; align-items: start;">
                            <div style="font-weight: 600; font-size: 11px; color: #64748b;">COMPANY HEALTH:</div>
                            <div style="font-size: 12px; color: #0f172a; font-weight: 600;">üìà IMPROVING: Company demonstrating strength and growth</div>
                        </div>
                    </div>
                </div>
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Jen Boorer</td>
                    </tr>
                    
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">KEY METRICS:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">90%, 70%</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
22 Oct 2025 07:00
RNS Number : 2931E
Trellus Health PLC
22 October 2025
Trellus Health plc
("Trellus Health", the "Company" or the "Group")
Contract Signed with Leading Global CRO
LONDON, U.K. AND NEW YORK, U.S. (22 October 2025)
. Trellus Health¬Æ plc (AIM: TRLS), a healthcare company delivering Trellus Elevate¬Æ, a digital platform that integrates data analytics with personalised, scientifically proven resilience programs and value-based solutions to manage complex chronic conditions, announces that, further to yesterday's announcement that it is in late stage contracting discussions, it has signed a 12 month contract (the "Contract") with one of the largest global Clinical Research Organisations (CROs), to support recruitment and enrolment optimisation for an ongoing mid-stage clinical trial in the field of immunology and inflammation. The Contract is due to commence later this year.
The clinical trials sector remains a strategic growth area for the Group and, accordingly, the Company has launched Trellus TrialSet‚Ñ¢. This program is designed to support potential clinical trial participants by identifying individuals with low resilience, who may be hesitant to enrol in the trial, and provide structured services to strengthen their readiness.
By leveraging the Company's proprietary resilience methodology alongside behavioural science, tailored education, and personalised engagement, Trellus TrialSet‚Ñ¢ enables participants to move from uncertainty to confidence, ensuring they are prepared to successfully enter and remain in the trial. This is expected to enhance recruitment efficiency, improve retention, and deliver cost savings for partners. The Contract, which includes an upfront fee, a monthly management fee, and milestone payments, is structured around three key performance indicators: (i) the number of potential eligible participants opting into the Trellus TrialSet‚Ñ¢ programme, (ii) the increase in qualified participants referred for screening, and (iii) the reduction in the screen failure rate.
As further announced yesterday, Trellus Health¬Æ has also now been granted preferred vendor status ("Preferred Vendor Status") by a second leading global contract research organisation (CRO) and negotiations continue to support recruitment for an additional clinical program. Whilst the granting of Preferred Vendor Status is not revenue generating in itself, it reinforces the strength and differentiation of Trellus Health's offering in the clinical trials vertical and provides direct access to the CRO's client base as well as accelerating procurement and contracting timelines.
Dr. Marla Dubinsky, Chief Executive Officer of Trellus Health, said:
"Clinical trials continue to face challenges in recruitment, retention and study completion. We are proud to launch Trellus TrialSet‚Ñ¢ to directly address these issues by proactively assessing and preparing participants, ensuring only those who are ready will enter the trial. This resilience-based approach is designed to significantly reduce screen failures and dropouts while delivering meaningful cost savings for our partners.
We are pleased to announce this partnership with a leading global CRO. While it does not immediately extend the Company's current cash runway beyond early December, it reflects our ability to secure contracts with leading CROs and represents an important step in building commercial traction. In addition, our designation as a preferred vendor by a second leading CRO for supporting recruitment for an additional clinical trial program further strengthens our position in the clinical trial vertical.
We will provide further updates in due course, as appropriate."
Regulatory Information
This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. Upon the publication of this announcement, this inside information is now considered to be in the public domain.
Enquiries:
Trellus Health plc
https://trellushealth.com/
Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder
Via Walbrook PR
Joy Bessenger, Chief Financial Officer
Singer Capital Markets
Jen Boorer / James Todd / Patrick Weaver
Tel: +44 (0)20 7496 3000
Walbrook PR
Tel: +44 (0)20 7933 8780 or
trellus@walbrookpr.com
Paul McManus / Lianne Applegarth /
Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303/
Alice Woodings
+44 (0)7407 804 654
About Trellus Health plc (www.trellushealth.com)
Trellus Health¬Æ (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.
Trellus Health¬Æ integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate¬Æ, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying the Trellus Elevate¬Æ methodology resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions and therapeutic areas, Trellus Health¬Æ considers its approach to have potential utility and demand across many conditions.
The Company also offers Trellus TrialSet‚Ñ¢, a solution for pharmaceutical partners spanning clinical trials to commercialisation, applying the same validated resilience science and platform to support trial success and long-term patient engagement
The Company was founded by Icahn School of Medicine at Mount Sinai faculty members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading experts in treating both the physical and emotional impacts of IBD, with a combined 50 years of pioneering whole-person healthcare innovation.
Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit:
www.trellushealth.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
CNTPPGQGUUPAPUG
                </div>
            </details>
            
            </div>
            
            </div>
            <div style="
                margin-top: 20px;
                padding: 14px 16px;
                background: linear-gradient(135deg, #fef3c7 0%, #fde68a 100%);
                border-radius: 10px;
                font-size: 12px;
                color: #78350f;
                border-left: 3px solid #f59e0b;
                display: flex;
                align-items: flex-start;
                gap: 10px;
            ">
                <span style="font-size: 16px; margin-top: 2px;">üéØ</span>
                <div style="line-height: 1.5;">
                    <strong style="display: block; margin-bottom: 4px;">Trader-Focused Analysis:</strong>
                    Each RNS includes sentiment classification, key data extraction, and trading context. 
                    Color-coded badges indicate bullish (green), bearish (red), or neutral (blue) signals.
                    <strong style="margin-top: 6px; display: block; font-size: 10px; opacity: 0.8;">
                    ‚ö†Ô∏è This is analysis of regulatory news for informational purposes. Not investment advice.
                    </strong>
                </div>
            </div>
        </div>
        
        <style>
            @keyframes slideDown {
                from {
                    opacity: 0;
                    transform: translateY(-10px);
                }
                to {
                    opacity: 1;
                    transform: translateY(0);
                }
            }
            details[open] > summary {
                background: linear-gradient(135deg, #eff6ff 0%, #f0f9ff 100%) !important;
                border-left-color: #0369a1 !important;
            }
            summary::-webkit-details-marker {
                display: none;
            }
            
            /* ========== MOBILE RESPONSIVE ========== */
            @media (max-width: 768px) {
                body {
                    padding: 10px;
                    font-size: 14px;
                }
                
                .container {
                    margin: 0 auto;
                }
                
                .header-card {
                    padding: 14px;
                    margin-bottom: 12px;
                    border-radius: 12px;
                }
                
                .company-name {
                    font-size: 22px;
                    margin-bottom: 8px;
                    line-height: 1.2;
                }
                
                .ticker-badge {
                    font-size: 13px;
                    padding: 6px 12px;
                }
                
                .company-meta {
                    gap: 8px;
                    flex-direction: row;
                    flex-wrap: wrap;
                }
                
                .meta-item {
                    padding: 6px 12px;
                    font-size: 12px;
                    gap: 6px;
                }
                
                .meta-icon {
                    font-size: 14px;
                }
                
                .score-hero {
                    padding: 20px;
                    margin-bottom: 12px;
                    border-radius: 12px;
                }
                
                .action-display {
                    font-size: 18px !important;
                    margin-bottom: 12px;
                }
                
                .scores-row {
                    gap: 16px;
                    margin: 20px 0;
                    justify-content: center;
                    flex-wrap: wrap;
                    display: flex;
                }
                
                .score-circle {
                    width: 110px;
                    height: 110px;
                    flex-shrink: 0;
                }
                
                .score-number {
                    font-size: 32px;
                }
                
                .score-label {
                    font-size: 10px;
                    margin-top: 4px;
                }
                
                .timing-badge-large {
                    padding: 10px 20px;
                    font-size: 14px;
                    margin: 12px 0;
                }
                
                .thesis-line {
                    font-size: 14px;
                    padding: 12px;
                    margin-top: 12px;
                }
                
                .factors-list {
                    grid-template-columns: 1fr;
                    gap: 10px;
                    margin-top: 12px;
                }
                
                .factor-item {
                    padding: 12px;
                    font-size: 12px;
                    gap: 8px;
                }
                
                .factor-icon {
                    font-size: 16px;
                }
                
                .cards-grid {
                    grid-template-columns: 1fr;
                    gap: 12px;
                    margin-bottom: 12px;
                }
                
                .card {
                    padding: 16px;
                    border-radius: 12px;
                }
                
                .card-title {
                    font-size: 14px;
                    margin-bottom: 12px;
                    gap: 8px;
                }
                
                .card-icon {
                    font-size: 18px;
                }
                
                .stat-row {
                    padding: 8px 0;
                    flex-wrap: wrap;
                    gap: 10px;
                }
                
                .stat-label {
                    font-size: 12px;
                }
                
                .stat-value {
                    font-size: 14px;
                }
                
                .rally-badge {
                    padding: 4px 10px;
                    font-size: 10px;
                }
                
                .risk-indicator {
                    gap: 10px;
                    padding: 12px;
                    flex-wrap: wrap;
                }
                
                .risk-icon {
                    font-size: 20px;
                }
                
                .reason-item {
                    padding: 12px;
                    margin-bottom: 10px;
                }
                
                .tag {
                    padding: 3px 8px;
                    font-size: 10px;
                }
                
                .footer {
                    padding: 12px;
                    font-size: 11px;
                    margin-top: 12px;
                    border-radius: 12px;
                }
                
                .alert-box {
                    padding: 12px;
                    margin: 10px 0;
                }
            }
            
            @media (max-width: 480px) {
                body {
                    padding: 8px 6px;
                }
                
                .header-card {
                    padding: 10px;
                    margin-bottom: 10px;
                    border-radius: 8px;
                }
                
                .company-name {
                    font-size: 18px;
                    margin-bottom: 6px;
                    line-height: 1.2;
                }
                
                .ticker-badge {
                    font-size: 11px;
                    padding: 3px 8px;
                }
                
                .company-meta {
                    gap: 4px;
                    flex-direction: column;
                }
                
                .meta-item {
                    padding: 4px 6px;
                    font-size: 11px;
                    background: rgba(247, 250, 252, 0.7);
                }
                
                .score-hero {
                    padding: 12px;
                    margin-bottom: 10px;
                    border-radius: 12px;
                }
                
                .score-circle {
                    width: 70px;
                    height: 70px;
                    flex-shrink: 0;
                }
                
                .score-number {
                    font-size: 22px;
                    font-weight: 800;
                }
                
                .score-label {
                    font-size: 7px;
                    margin-top: 2px;
                }
                
                .scores-row {
                    flex-direction: column;
                    gap: 10px;
                    margin: 12px 0;
                    align-items: center;
                }
                
                .timing-badge-large {
                    padding: 6px 12px;
                    font-size: 11px;
                    margin: 10px 0;
                }
                
                .thesis-line {
                    font-size: 11px;
                    padding: 8px;
                    line-height: 1.3;
                }
                
                .card {
                    padding: 10px;
                    margin-bottom: 8px;
                    border-radius: 8px;
                }
                
                .card-title {
                    font-size: 12px;
                    margin-bottom: 8px;
                    font-weight: 700;
                }
            }
        </style>
        

        <!-- Footer -->
        <div class="footer">
            Report generated: 2026-01-17 ‚Ä¢ CrashDash APEX Engine<br>
            <strong>‚ñ≥ Not financial advice. Do your own research.</strong>
        </div>

    </div>
</body>
</html>